€1.77
-0.03 (-1.77%)
EUR · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where IPH.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
17 interventional · 5 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of IPH4502 in Patients With Advanced Solid TumorsNCT06781983Safety and TolerabilityOpen-label · Treatment | Phase 1 | Active, not recruiting | Drug: IPH4502 | Advanced or Metastatic Solid Tumors | 145 | Apr 2028 | ≤ 619 d | 2026-07-27 |
| IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)NCT05742607Pathological Complete Response (pCR)Open-label · Treatment | Phase 2 | Recruiting | Drug: IPH5201 + durvalumab + standard chemotherapy | Non Small Cell Lung Cancer | 70 | Jun 2027 | ≤ 314 d | 2026-06-17 |
| Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin LymphomaNCT06088654Safety and tolerabilityOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Following Completion of dose escalation, the study has been discontinued as part of the Company's strategic priorization of its pipeline. | Drug: IPH6501 | Non Hodgkin Lymphoma | 23 | 2026-02-06actual | — | 2026-04-14 |
| IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell LymphomaNCT03902184Objective Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Biological: IPH4102 | Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome | 170 | 2026-01-08actual | — | 2026-04-29 |
| Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2NCT05321147Occurrence of adverse events (AEs)Open-label · Treatment | Phase 1 | Completed | Biological: lacutamab | Peripheral T Cell Lymphoma | 20 | 2023-11-19actual | — | 2024-03-28 |
| Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT02643550Occurrence of Dose Limiting Toxicities (DLT) in the dose escalation part of the studyNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: Monalizumab, Cetuximab, Anti-PD(L)1 | Head and Neck Neoplasms | 143 | 2023-03-28actual | — | 2023-05-12 |
| IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid TumorsNCT03665129Occurrence of Drug Limited Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: early termination | Biological: IPH5401 and Durvalumab | Advanced Solid Tumors | 73 | 2021-02-24actual | — | 2022-01-27 |
| Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)NCT02593045Occurrence of Dose Limiting Toxicities (DLT)Open-label · Treatment | Phase 1 | Completed | Biological: IPH4102 | Cutaneous T-Cell Lymphoma | 44 | Apr 2020actual | — | 2021-01-20 |
| Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLLNCT02557516results2019-12-17Number of Dose Limiting ToxicitiesNon-randomized · Open-label · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: monalizumab | Chronic Lymphocytic Leukemia | 22 | 2018-10-29actual | — | 2019-12-17 |
| Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral CavityNCT02331875best objective response rateOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: lack of recruitment | Drug: IPH2201 · Procedure: Standard Surgery · Radiation: Postsurgical Adjuvant Therapy | Squamous Cell Carcinoma of the Oral Cavity | 3 | Dec 2016actual | — | 2017-01-04 |
| Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)NCT01687387results2019-02-08Leukemia-Free SurvivalRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: IPH2102 at 0.1 mg/kg, IPH2102 at 1 mg/kg, Placebo (normal saline solution) | Acute Myeloid Leukemia | 152 | 2016-11-17actual | — | 2019-02-08 |
| Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid ArthritisNCT01370902Incidence of adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: NNC 0141-0000-0100, placebo, NNC 0141-0000-0100, placebo, NNC 0141-0000-0100, placebo | Inflammation, Rheumatoid Arthritis | 92 | Mar 2014actual | — | 2014-12-23 |
| Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second RelapseNCT01217203number of patients with Dose Limiting Toxicity (DLT) at each dose levelOpen-label · Treatment | Phase 1 | Completed | Drug: IPH2101 combined to lenalidomide | Patients With Multiple Myeloma Experiencing a, First or Second Relapse | 15 | Dec 2013actual | — | 2014-02-28 |
| A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid LeukaemiaNCT01256073To assess safety and tolerability of repeating dosings of Anti-KIR(1-7F9)Open-label · Treatment | Phase 1 | Completed | Drug: IPH2101 | Acute Myeloid Leukemia | 21 | Jul 2013actual | — | 2014-02-28 |
| Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple MyelomaNCT01222286results2014-05-09Rate of Patients Achieving an Objective ResponseRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: IPH2101 | Smoldering Multiple Myeloma | 30 | Jul 2012actual | — | 2026-05-14 |
| Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple MyelomaNCT00999830results2016-03-24Rate of Patients Achieving a Response Based on M-protein or Free Light ChainsRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: IPH2101 | Multiple Myeloma | 27 | Jun 2012actual | — | 2016-03-24 |
| An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple MyelomaNCT00552396results2012-06-28Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 TreatmentOpen-label · Treatment | Phase 1 | Completed | Drug: Anti-KIR (1-7F9) | Multiple Myeloma | 32 | Jan 2011actual | — | 2016-03-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19